Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the die has not been cast
Ann Oncol
.
2022 Jun;33(6):658-659.
doi: 10.1016/j.annonc.2022.03.007.
Epub 2022 Mar 16.
Authors
B Tomasik
1
,
M Bieńkowski
2
,
J Jassem
3
Affiliations
1
Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdansk, Poland.
2
Department of Pathomorphology, Medical University of Gdańsk, Gdańsk, Poland.
3
Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdansk, Poland. Electronic address: jjassem@gumed.edu.pl.
PMID:
35306157
DOI:
10.1016/j.annonc.2022.03.007
No abstract available
Publication types
Letter
Comment
MeSH terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Humans
Neoadjuvant Therapy*
Platinum / therapeutic use
Triple Negative Breast Neoplasms* / drug therapy
Substances
Platinum